Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT - Free Report) from a sell rating to a hold rating in a research note published on Thursday.

Several other analysts have also issued reports on the company. Canaccord Genuity Group cut their price target on Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Citigroup reissued a "buy" rating on shares of Arcturus Therapeutics in a report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Arcturus Therapeutics in a report on Thursday, April 10th. BTIG Research set a $48.00 price target on Arcturus Therapeutics and gave the company a "buy" rating in a report on Monday, March 10th. Finally, Wells Fargo & Company cut their price target on Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $57.80.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock traded down $0.60 during mid-day trading on Thursday, reaching $12.20. 353,268 shares of the stock traded hands, compared to its average volume of 451,437. The stock has a market capitalization of $330.88 million, a PE ratio of -5.50 and a beta of 2.36. Arcturus Therapeutics has a 12-month low of $8.04 and a 12-month high of $45.00. The business's 50-day moving average is $11.37 and its 200-day moving average is $14.97.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($1.58) by $1.06. The company had revenue of $29.38 million during the quarter, compared to analysts' expectations of $25.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. Equities analysts anticipate that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcturus Therapeutics

Hedge funds have recently made changes to their positions in the business. Byrne Asset Management LLC boosted its stake in shares of Arcturus Therapeutics by 89.8% in the first quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 1,365 shares during the period. US Bancorp DE boosted its stake in shares of Arcturus Therapeutics by 218.9% in the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 2,329 shares during the period. Virtus ETF Advisers LLC boosted its stake in shares of Arcturus Therapeutics by 38.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock worth $69,000 after acquiring an additional 1,132 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Arcturus Therapeutics in the fourth quarter worth about $71,000. Finally, National Bank of Canada FI boosted its stake in shares of Arcturus Therapeutics by 639.6% in the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company's stock worth $94,000 after acquiring an additional 4,784 shares during the period. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.